<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515043</url>
  </required_header>
  <id_info>
    <org_study_id>INVAC1-CT-102</org_study_id>
    <nct_id>NCT04515043</nct_id>
  </id_info>
  <brief_title>EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)</brief_title>
  <official_title>AN EXPLORATORY FOLLOW-UP STUDY OF LONG TERM ANTI-TELOMERASE IMMUNE RESPONSE AFTER INVAC-1 VACCINATION IN PATIENTS WITH LONG TERM SURVIVAL. Addendum to INVAC1-CT-101 PROTOCOL - EUDRACT NUMBER : 2013-004369-15</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Invectys</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Invectys</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an exploratory study of long term immunogenicity of INVAC-1 in patients&#xD;
      who participated in the INVAC1-CT-101 phase I study (between 2014 and 2018).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of the study is to analyze anti-telomerase specific memory responses in&#xD;
      blood of long term survival patients and to correlate these immune responses to their&#xD;
      subsequent treatment since the end of INVAC1-CT-101 phase I study. Six patients are expected&#xD;
      to participate in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Actual">December 19, 2020</completion_date>
  <primary_completion_date type="Actual">December 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>long term anti telomerase specific memory responses</measure>
    <time_frame>1 day visit</time_frame>
    <description>will be measured by ELISPOT on blood of patients who were treated by INVAC-1 in the phase I NCT02301754 study and are still alive at the present time</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>INVAC-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients have been treated by INVAC-1 vaccine during the previous phase 1 NCT02301754. No new treatment injection is required in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.</intervention_name>
    <description>blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine</description>
    <arm_group_label>INVAC-1</arm_group_label>
    <other_name>blood sampling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who participated in the phase I study and are still alive at the present time&#xD;
&#xD;
          2. Ability to provide written informed consent and to understand and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anemia (Hgb &lt; 7g/dL) according to L-1121-1 annexe 2 of Code de Sant√© Publique&#xD;
&#xD;
          2. Systolic blood pressure below 90 mm Hg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Teixeira</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Paris Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

